Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses .
用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。
Hospital Vera Cruz, Campinas, São Paulo, Brazil
Sherief Abd-Elsalam, Tanta, Egypt
Materno-Perinatal Hospital "Mónica Pretelini", Toluca, Mexico
Tanta University, Assiut University, Tanta, Egypt
Sherief Abd-Elsalam, Tanta, Egypt
The Chappel Group Research, Kissimmee, Florida, United States
Chicago Medical Research Institute, Inc., Chicago, Illinois, United States
Chicago Clinical Research Institute, Inc., Chicago, Illinois, United States
Hospital Vera Cruz, Campinas, São Paulo, Brazil
Centro de Genomas, São Paulo, Brazil
Hospital Emílio Ribas, São Paulo, Brazil
The Chappel Group Research, Kissimmee, Florida, United States
Clinical Trial Specialists, Inc., Acworth, Georgia, United States
Centex Studies, Inc., Houston, Texas, United States
Materno-Perinatal Hospital "Mónica Pretelini", Toluca, Mexico
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.